
Table of Contents

Introduction..... 1

Part One – FDA Guidance Documents

A Guide to Informed Consent - Information Sheet: Guidance for Institutional Review Boards and Clinical Investigators 5

This document provides information on content and format of consent documents.

Questions and Answers on Informed Consent Elements 15

This document is directed to small business entities to help them understand the new requirement to include information on the availability of clinical trial data in informed consent documents.

Exception from Informed Consent Requirements for Emergency Research..... 25

This guidance is intended to assist Institutional Review Boards, clinical investigators and sponsors in the development, conduct and oversight of investigations to determine the safety and effectiveness of FDA-regulated products in emergency settings when an exception from the informed consent requirements is requested.

IDE Informed Consent..... 89

This document is designed to assist entities in complying with regulations governing how to obtain adequate informed consent while operating a clinical trial under an Investigational Device Exemption.

In Vitro Diagnostic Device Studies - Frequently Asked Questions 95

This guidance document outlines FDA regulations applicable to studies for investigational IVD devices, including those regulations related to human subject protection.

Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable 149

The FDA issued this guidance to inform sponsors, institutional review boards, clinical investigators and agency staff that the FDA intends to exercise enforcement discretion, under certain circumstances, with respect to its current regulations governing the requirement for informed consent when human specimens are used for FDA-regulated in vitro diagnostic device investigations.

Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs	159
---	-----

This guidance provides recommendations to blood establishments for obtaining written informed consent from prospective Source Plasma donors participating in a plasmapheresis program or an immunization program.

MaPP 6030.2 - INDs: Review of Informed Consent Documents	169
--	-----

This MaPP is for medical officers and project managers. It describes (1) when an informed consent document (ICD) submitted under an investigational new drug application (IND) should be reviewed, (2) when the Center for Drug Evaluation and Research (CDER) should request that an ICD be submitted to an IND, and (3) procedures for reviewing an ICD, when necessary.

MaPP 6030.8 - INDs: Exception from Informed Consent Requirements for Emergency Research.....	175
--	-----

This MaPP describes the procedures for processing an investigational new drug application (IND) for emergency research in which the clinical investigation described includes a request for an exception from the requirement to obtain informed consent from all study subjects.

Part Two – OHRP Documents

Advanced Notice of Proposed Rulemaking - Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators.....	185
--	-----

OHRP published this advanced notice of proposed rulemaking to seek comment on how to better protect human subjects who are involved in research, while facilitating valuable research and reducing burden, delay and ambiguity for investigators.

Advanced Notice of Proposed Rulemaking - Comparison of Existing Rules with Some of the Changes Being Considered.....	205
--	-----

This table provides an overview of current human subjects research protection regulation compared to proposed changes.

Informed Consent – FAQs	211
-------------------------------	-----

This document provides answers to common questions about OHRP informed consent requirements.

Informed Consent Checklist - Basic and Additional Elements.....	235
---	-----

This checklist provides step-by-step guidance for preparing informed consent documents.

Tips on Informed Consent.....	239
<i>OHRP provides guidance to investigators for developing an approach and proposed language for obtaining informed consent.</i>	
Guidance on Exculpatory Language in Informed Consent.....	243
<i>This document provides guidance on the regulatory prohibition on the inclusion of exculpatory language in informed consent. The document includes examples of acceptable language as well as examples of language that would be considered exculpatory.</i>	
Applicability of 45 CFR part 46 to Clinical Investigations Conducted Under FDA’s Interim Final Rule at 21 CFR 50.23(e).....	251
<i>This document addresses how to determine whether the regulations at 45 CFR Part 46 are applicable to the activities covered by the FDA’s regulations on exemption from informed consent requirements.</i>	
Compliance Oversight Activities: Determinations of Noncompliance.....	257
<i>This section of OHRP’s guide to compliance oversight describes situations considered to be noncompliant with informed consent requirements.</i>	
Informed Consent—Legally Effective and Prospectively Obtained.....	261
<i>The purpose of this letter to institutional officials and IRB chairs is to reiterate the mandate for obtaining legally effective informed consent prospectively from each research subject or the subject’s legally authorized representative.</i>	
Guidance on Important Considerations for When Participation of Human Subjects in Research is Discontinued.....	263
<i>This document provides guidance on important considerations for when participation of human subjects in research is discontinued, either because a subject voluntarily chooses to discontinue participation during the course of the research, or because an investigator terminates a subject’s participation in the research without regard to the subject’s consent.</i>	
Informed Consent Requirements in Emergency Research	283
<i>This document outlines requirements for obtaining and documenting informed consent for a strictly limited class of research, involving research activities that may be carried out in human subjects who are in need of emergency therapy and for whom, because of the subjects’ medical condition and the unavailability of legally authorized representatives of the subjects, no legally effective informed consent can be obtained.</i>	

Obtaining and Documenting Informed Consent of Subjects Who Do Not Speak English.....289

This document recommends that the written consent document should embody, in language understandable to the subject, all the elements necessary for legally effective informed consent. Subjects who do not speak English should be presented with a consent document written in a language understandable to them.

Human Subject Regulations Decision Charts293

OHRP provides these charts as guides for deciding if an activity is research involving human subjects that must be reviewed by an IRB under the requirements 45 CFR Part 46.

Part Three – Code of Federal Regulations

21 CFR Part 50 – Protection of Human Subjects (FDA).....309

45 CFR Part 46 – Protection of Human Subjects (OHRP)323